1. Home
  2. KPTI vs ANIX Comparison

KPTI vs ANIX Comparison

Compare KPTI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • ANIX
  • Stock Information
  • Founded
  • KPTI 2008
  • ANIX 1982
  • Country
  • KPTI United States
  • ANIX United States
  • Employees
  • KPTI N/A
  • ANIX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • ANIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • ANIX Health Care
  • Exchange
  • KPTI Nasdaq
  • ANIX Nasdaq
  • Market Cap
  • KPTI 81.1M
  • ANIX 82.7M
  • IPO Year
  • KPTI 2013
  • ANIX 1987
  • Fundamental
  • Price
  • KPTI $0.62
  • ANIX $3.14
  • Analyst Decision
  • KPTI Strong Buy
  • ANIX Strong Buy
  • Analyst Count
  • KPTI 4
  • ANIX 2
  • Target Price
  • KPTI $5.00
  • ANIX $8.50
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • ANIX 128.9K
  • Earning Date
  • KPTI 02-19-2025
  • ANIX 03-11-2025
  • Dividend Yield
  • KPTI N/A
  • ANIX N/A
  • EPS Growth
  • KPTI N/A
  • ANIX N/A
  • EPS
  • KPTI N/A
  • ANIX N/A
  • Revenue
  • KPTI $148,442,000.00
  • ANIX N/A
  • Revenue This Year
  • KPTI $4.47
  • ANIX N/A
  • Revenue Next Year
  • KPTI $7.35
  • ANIX N/A
  • P/E Ratio
  • KPTI N/A
  • ANIX N/A
  • Revenue Growth
  • KPTI 1.77
  • ANIX N/A
  • 52 Week Low
  • KPTI $0.58
  • ANIX $2.07
  • 52 Week High
  • KPTI $1.70
  • ANIX $4.20
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • ANIX 60.67
  • Support Level
  • KPTI $0.58
  • ANIX $2.87
  • Resistance Level
  • KPTI $0.67
  • ANIX $3.22
  • Average True Range (ATR)
  • KPTI 0.05
  • ANIX 0.18
  • MACD
  • KPTI -0.00
  • ANIX 0.02
  • Stochastic Oscillator
  • KPTI 31.02
  • ANIX 81.67

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: